Compare Natera Inc. Common Stock (NTRA) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $69 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 5.7× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Tax Managed Fund FTSE Developed Markets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 132 Days on average.
| NTRA | VEA | |
|---|---|---|
Market Cap | $57.03B | $323.80B |
Volume | 1,131,157 | 10,680,748 |
Sector | Health | — |
52-Week High | $425.64 | $73.79 |
52-Week Low | $179.42 | $58.90 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VEA trades at $70.06 with minimal daily movement (+0.16%). The technical outlook is bearish with moving averages signaling weakness, though oscillators remain neutral. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. Institutional activity shows mixed signals with some firms increasing positions while others reduced exposure.
The ETF's focus on developed international markets provides stability but faces currency and geopolitical risks. Current bearish technical signals suggest near-term caution, though the fund's cost efficiency and diversification benefits support long-term international exposure. Key risks include global economic slowdowns and currency fluctuations affecting returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
